Search
Pitolisant
go.drugbank.com/drugs/DB11642ApprovedInvestigational[A32025] About 60-70% of patients with narcolepsy experience cataplexy, which is a sudden loss of muscle tone triggered by positive or negative emotions. … [A32024] The therapeutic effectiveness of pitolisant was comparable to that of [modafinil].
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP2B6 InducersTrovafloxacin
go.drugbank.com/drugs/DB00685ApprovedWithdrawnIt was shown to be more effective against Gram-positive bacteria than Gram-negative bacteria when compared to previous fluoroquinolones. … Due to its hepatotoxic potential, trovafloxacin was withdrawn from the market.
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme InhibitorsRezafungin
go.drugbank.com/drugs/DB16310ApprovedInvestigationalRezafungin has a half-life higher than 130 hours and can be administered once a week instead of daily. … It can only be administered intravenously but does not reach therapeutic concentrations in the central nervous system, eye and urine.
Synonyms: Echinocandin B, 1-((4R,5R)-4-hydroxy-N2-((4''-(pentyloxy)(1,1':4',1''-terphenyl)-4-yl)carbonyl)-5-(2-(trimethylammonio)ethoxy)-l-ornithine)-4-((4S)-4-hydroxy-4-(4-hydroxyphenyl)-l-allothreonine)-Grepafloxacin
go.drugbank.com/drugs/DB00365ApprovedWithdrawnDue to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States … Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsTrofinetide
go.drugbank.com/drugs/DB06045Approved[A258438] Trofinetide was approved by the FDA on March 10, 2023, for the treatment of Rett syndrome,[L45718,L45748] which is an X-linked neurodevelopmental disorder characterized by a range of cognitive … [A258438] Trofinetide is believed to work by reducing inflammation and apoptosis of neurons.
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors16S/23S rRNA (cytidine-2'-O)-methyltransferase TlyA
go.drugbank.com/bio_entities/BE0009727TargetMycobacterium tuberculosis (strain ATCC 25618 / H37Rv)Acts as a host evasion factor, that significantly contributes to the pathogenesis of M.tuberculosis by modulating adaptive immune responses by inhibiting host-protective Th1 and Th17 cytokine responses … Catalyzes the 2'-O-methylation at nucleotides C1409 in 16S rRNA and C1920 in 23S rRNA (PubMed:16857584, PubMed:20854656). Is likely involved in ribosomal biogenesis (PubMed:21443791).
Polypeptides: 16S/23S rRNA (cytidine-2'-O)-methyltransferase TlyASynonyms: 16S rRNA (cytidine1409-2'-O)-methyltransferaseCrotalus atrox antivenin
go.drugbank.com/drugs/DB13892ApprovedThe majority of people bitten are males and about 50% occur in the age group of 18 to 28 [F113]. … It is intravenously (IV) administered to prevent/limit systemic toxicity [FDA label].
Etorphine
go.drugbank.com/drugs/DB01497ExperimentalIllicitVet approvedEtorphine is only available to the patients under an official prescription. In the US, Etorphine is listed as a Schedule I drug, although Etorphine hydrochloride is classified as Schedule II. … In certain countries, etorphine is classified as a Schedule 1 drug and hence, in these countries, it can be used legally only by health professionals and for research purposes.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeHypochlorous acid
go.drugbank.com/drugs/DB14135InvestigationalAn oxyacid of chlorine (HClO) containing monovalent chlorine that acts as an oxidizing or reducing agent.
Mixtures: K-100, K-100Products: Tok and Care Sanitizer, CELA No-clean hypochlorous acid disinfectantGanaxolone
go.drugbank.com/drugs/DB05087ApprovedInvestigational[A3197] Ganaxolone belongs to a class of compounds referred to as neurosteroids. … [A3197] Endogenous neurosteroids, which comprise certain metabolites of progesterone and deoxycorticosterone, bind potently and specifically to GABA<sub>A</sub> receptors to enhance their inhibitory effects
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 Substrates